Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.

Clinical Trials

Discovery & Development Clinical Trials

Of Men and Mice

| James Strachan

Male animal bias in preclinical research isn’t scientifically justified and may be skewing our understanding of the brain.

Discovery & Development Clinical Trials

Choice Matters

| Maryam Mahdi

A new vaccine could help give people at risk of HIV more options.

Manufacture Analytical Science

Doing it For the Kids

| Maryam Mahdi

Pfizer’s latest investment in the UK targets an improvement in pediatric clinical trials.

Discovery & Development Clinical Trials

Giving Data the Gift of Meaning

| Gen Li, Jonathan Peachey

Clinical trials need an overhaul – and AI is the solution.

Business & Regulation Clinical Trials

Brexit Realities

| James Strachan

Our animation explores the unique challenges a "no-deal" Brexit poses for the drug development and advanced therapy sectors.

Business & Regulation Business Practice

How to Commercialize an Orphan Drug

| George A. Chressanthis, Animesh Arun

Orphan drugs for rare diseases represent a significant unmet medical need for pharma, but commercialication can be tricky...

Discovery & Development Clinical Trials

Out With the Old and in With AI

| Chris Tackaberry

Artificial Intelligence and other innovative technologies have the potential to disrupt every stage of the clinical trial process.

Discovery & Development Advanced Medicine

Perusing the Pipeline

| James Strachan

With cell and gene therapies being all the rage, we take a peek at some of the advanced therapies coming down the pipe.

Discovery & Development Clinical Trials

With Age Comes Challenges But Not Trials

| Maryam Mahdi, Stephanie Sutton

A key focus of Andrew McLachlan’s career is understanding the impact of aging on drug disposition and response to medicines.

Business & Regulation Business Practice

Facing the Brexit Trial

| James Strachan

No-deal Brexit poses unique challenges for the development and advanced therapy sectors, not least tight timelines and a limited ability to stockpile.

Newsletter

Send me the latest from The Medicine Maker.

Sign up now

Sister Publications

You might be interested in our Sister Publications:

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register